The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status


  • Elinborg J. Olafsdottir
  • Ake Borg
  • Maj Britt Jensen
  • Anne Marie Gerdes
  • Anna L.V. Johansson
  • Rosa B Barkardottir
  • Oskar T. Johannsson
  • Bent Ejlertsen
  • Ida Marie Heeholm Sønderstrup
  • Eivind Hovig
  • Anne Vibeke Lænkholm
  • Thomas van Overeem Hansen
  • Gudridur H. Olafsdottir
  • Maria Rossing
  • Jon G. Jonasson
  • Stefan Sigurdsson
  • Niklas Loman
  • Martin P. Nilsson
  • Steven A. Narod
  • Laufey Tryggvadottir

Summary, in English

Background: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). Conclusions: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.


  • LUCC: Lund University Cancer Centre
  • Familial Breast Cancer
  • Breastcancer-genetics
  • Tumor microenvironment

Publishing year







British Journal of Cancer





Document type

Journal article


Nature Publishing Group


  • Cancer and Oncology
  • Public Health, Global Health, Social Medicine and Epidemiology



Research group

  • Familial Breast Cancer


  • ISSN: 0007-0920